Amy Halseth

Dr. Halseth has over 20 years of experience in the pharmaceutical industry across all phases of drug development. Prior to Samumed, Dr. Halseth was Vice President of Global Development at Orexigen Therapeutics, where she contributed to multiple marketing approvals in the US, EU, Canada, and Australia, and also was the medical lead for development and marketing collaborations around the globe. She has previously held positions spanning the drug development pipeline from Discovery Research through Medical Affairs at companies including Pfizer, Amylin Pharmaceuticals, Genentech, and Neurana Pharmaceuticals. Dr. Halseth has worked across a variety of therapeutic areas, including diabetes, obesity, osteoporosis, acute pain, and cardiovascular disease and is the author of numerous scientific manuscripts.

Dr. Halseth received her Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University and her B.A. in Exercise Science from Occidental College.